Welcome to the international HTA database

Showing [22171 Records] Selected Records [0 Hits] [Clear]

Year	Source	Title
2023	National Authority for Assessment and Accreditation in Healthcare (INEAS)	[Kadcyla® (trastuzumab emtansine) in the treatment of HER2-positive breast cancer : A rapid review]
2023	NIHR Public Health Research (PHR) programme	A multicomponent psychosocial intervention to reduce substance use by adolescents involved in the criminal justice system: the RISKIT-CJS RCT
2023	Institute for Clinical Effectiveness and Health Policy (IECS)	[Triple-phase computed tomography in patients with liver lesion]
2023	NIHR Health Technology Assessment programme	Antidepressants in pregnancy: applying causal epidemiological methods to understand service-use outcomes in women and long-term neurodevelopmental outcomes in exposed children
2023	National Authority for Assessment and Accreditation in Healthcare (INEAS)	[Autologous adipose-derived stem cells for chronic wounds treatment : Full HTA report]
2023	NIHR Public Health Research (PHR) programme	Impact of a social prescribing intervention in North East England on adults with type 2 diabetes: the SPRING_NE multimethod study
2023	Institute for Clinical Effectiveness and Health Policy (IECS)	[Dielectric radiofrequency for the treatment of primary hyperhidrosis and bromhidrosis]
2023	NIHR Health Technology Assessment programme	Insights from UKCTOCS for design, conduct and analyses of large randomised controlled trials
2023	Institute for Clinical Effectiveness and Health Policy (IECS)	[Transbronchial biopsy guided by endobronchial ultrasound (EBUS) in pathologies accesible by transbronchial puncture that required anatomopathological diagnosis]
2023	NIHR Health Services and Delivery Research programme	Understanding what affects psychological morbidity in informal carers when providing care at home for patients at the end of life: a systematic qualitative evidence synthesis
2023	The Danish Health Technology Council (DHTC)	[Assessment concerning glucose monitoring for the treatment of adult patients with type 1 diabetes]
2023	Institute for Clinical Effectiveness and Health Policy (IECS)	[Invasive electroencephalography for drug-resistant epilepsy]
2023	NIHR Health Technology Assessment programme	Extracorporeal carbon dioxide removal compared to ventilation alone in patients with acute hypoxaemic respiratory failure: cost-utility analysis of the REST RCT
2023	Norwegian Institute of Public Health (NIPH)	[Brace compression for treatment of pectus carinatum: a rapid health technology assessment]
2023	Institut national d'excellence en sante et en services sociaux (INESSS)	[Guides and standards: the management of myalgic encephalomyelitis / chronic fatigue syndrome]
2023	Austrian Institute for Health Technology Assessment (AIHTA)	Robot-assisted surgery in thoracic and visceral indications – Update 2023
2023	Institut national d'excellence en sante et en services sociaux (INESSS)	[Guides and standards: Syphilis - detection, diagnosis, optimal antibiotic use, and follow-up]
2023	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Fenfluramine (Dravet syndrome, ≥ 2 years)]
2023	Institut national d'excellence en sante et en services sociaux (INESSS)	[Report: benchmarks to improve services for at-risk or neglected children and their families]
2023	Institut national d'excellence en sante et en services sociaux (INESSS)	[State of knowledge: organizational models for the management of spinal cord injuries]
2023	Institut national d'excellence en sante et en services sociaux (INESSS)	[Report: resuscitation in community opioid overdose ‒ update and complement to INESSS guidance published in 2018 - Cardiopulmonary resuscitation (CPR) in a context of community-based naloxone administration for opioid overdose]
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Fidanacogene elaparvovec (haemophilia B); assessment according to §35a Social Code Book (SGB) V; search for disease registries]
2023	Ontario Health	Robotic-assisted partial nephrectomy for kidney cancer
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ivosidenib (acute myeloid leukaemia, IDH1 R132 mutation, first line, combination with azacitidine) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2023	Ontario Health	Robotic-assisted hysterectomy for endometrial cancer in people with obesity
2023	Norwegian Institute of Public Health (NIPH)	[Triclosan coated sutures for prevention of surgical site infection: a health technology assessment]
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ivosidenib (cholangiocarcinoma) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2023	Ontario Health	Carrier screening programs for cystic fibrosis, fragile X syndrome, hemoglobinopathies and thalassemia, and spinal muscular atrophy
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Mirikizumab (ulcerative colitis) - Benefit assessment according to § 35a Social Code Book V]
2023	NIHR Health Technology Assessment programme	Tonsillectomy compared with conservative management in patients over 16 years with recurrent sore throat: the NATTINA RCT and economic evaluation
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Lumacaftor/ivacaftor (cystic fibrosis, 1 to < 2 years, F508del mutation, homozygous) – Benefit assessment according to §35a Social Code Book V]
2023	NIHR Health Technology Assessment programme	A multifaceted intervention to reduce antibiotic prescribing among CHIldren with acute COugh and respiratory tract infection: the CHICO cluster RCT
2023	Scottish Health Technologies Group (SHTG)	Tumour profiling tests to guide chemotherapy decisions in early breast cancer
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Dimethyl fumarate (relapsing remitting multiple sclerosis) –Benefit assessment according to §35a Social Code Book V]
2023	Scottish Health Technologies Group (SHTG)	Community based respiratory care services for patients with chronic respiratory conditions
2023	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Electromagnetic Navigation Bronchoscopy: Use in Dying for Lung Nodules Resection. Horizon Scanning Technologies]
2023	Scottish Health Technologies Group (SHTG)	Outpatient biopsies (re-usable and disposable) equipment for suspicious laryngeal and pharyngeal lesions
2023	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Robotic Bronchoscopy for Lung Nodule Diagnostics. Horizon Scanning Technologies]
2023	Scottish Health Technologies Group (SHTG)	The clinical effectiveness and cost effectiveness of a digital type 2 diabetes remission programme
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Evaluation of invitation letters and information for insured persons on colorectal cancer screening]
2023	Scottish Health Technologies Group (SHTG)	The cost-effectiveness of the Scottish Hip Fracture Audit
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Tremelimumab and durvalumab (NSCLC) – Second addendum to Project A23-29 \| A23-31]
2023	Scottish Health Technologies Group (SHTG)	Outpatient parenteral antimicrobial therapy (OPAT) cost calculator
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Selumetinib (neurofibromatosis) - Assessment according to §35a (para 1., sentence 11) Social Code Book V (expiry of the decision)]
2023	Scottish Health Technologies Group (SHTG)	Living donor transplantation
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Tremelimumab and durvalumab (NSCLC) - Addendum to Commissions A23-29 and A23-31]
2023	Center for Drug Evaluation (CDE)	[Latest trend in consumption and utilization of schedule I and II controlled drugs - a nationwide population-based data in Taiwan
2023	Scottish Health Technologies Group (SHTG)	Placental growth factor (PlGF)-based testing to help diagnose suspected preterm pre-eclampsia
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Durvalumab (malignant biliary tract cancer [BTC]) – Addendum to Commission A23-26]
2023	Health Information and Quality Authority (HIQA)	Health technology assessment of the addition of severe combined immunodeficiency (SCID) to the National Newborn Bloodspot Screening Programme
2023	Scottish Health Technologies Group (SHTG)	An assessment of the Feeling Good app
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Dupilumab (prurigo nodularis) – Addendum to Project A23-24]
2023	Scottish Health Technologies Group (SHTG)	Consideration of selective internal radiation therapies (SIRT) for treating primary hepatocellular carcinoma (liver cancer)
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Darolutamide (prostate cancer) - Addendum to Commission A23-21]
2023	Scottish Health Technologies Group (SHTG)	Store-and-forward teledermatology for triage of primary care referrals
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Esketamine (treatment-resistant major depressive disorder) – Addendum to Commission A23-18]
2023	Scottish Health Technologies Group (SHTG)	Orthotic bracing for the treatment of idiopathic scoliosis in children and young people (less than 18 years)
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Luspatercept (non-transfusion-dependent beta-thalassaemia) - Addendum to Commission A23-20]
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Axicabtagene ciloleucel (diffuse large B-cell lymphoma, second line) – Benefit assessment according to §35a Social Code Book V]
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Axicabtagene ciloleucel (DLBCL and PMBCL, third line) – Benefit assessment according to §35a Social Code Book V]
2023	Swiss Federal Office of Public Health (FOPH)	Oral anticoagulants for the prevention of stroke and systemic embolism in people with non-valvular atrial fibrillation
2023	Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU)	[Evaluation of taking mifepristone at home during a medical abortion]
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Concept for routine practice data collection for valoctocogene roxaparvovec acc. to the Law for More Safety in the Supply of Medicines (GSAV): Evaluation of the study protocol (Version 1.0) and the statistical analysis plan (Version1.0) – Second addendum to Commission A22-20]
2023	Institut national d'excellence en sante et en services sociaux (INESSS)	[State of knowledge: effectiveness of rehabilitation models and approaches for young people with adjustment problems]
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Axicabtagene ciloleucel (follicular lymphoma) – Benefit assessment according to §35a Social Code Book V]
2023	Swiss Federal Office of Public Health (FOPH)	Folate tests for suspected folate deficiency
2023	Agency for Healthcare Research and Quality (AHRQ)	Efficacy of dental services for reducing adverse events in those receiving chemotherapy for cancer
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Bimekizumab (non-radiographic axial spondyloarthritis) – Benefit assessment according to §35a Social Code Book V]
2023	Agency for Healthcare Research and Quality (AHRQ)	Efficacy of dental services for reducing adverse events in those undergoing insertion of implantable cardiovascular devices
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Bimekizumab (ankylosing spondylitis) – Benefit assessment according to §35a Social Code Book V]
2023	Swiss Federal Office of Public Health (FOPH)	Revascularisation versus optimal medical therapy (OMT) for the treatment of chronic coronary syndrome (CCS)
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Bimekizumab (psoriatic arthritis) – Benefit assessment according to §35a Social Code Book V]
2023	Swiss Federal Office of Public Health (FOPH)	Calcitonin gene-related peptide antagonists for the prevention of migraine
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Nivolumab (melanoma in adolescents, adjuvant) – Benefit assessment according to §35a Social Code Book V]
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Nivolumab (melanoma) – Benefit assessment according to §35a Social Code Book V]
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Riociguat (pulmonary arterial hypertension in children and adolescents) – Benefit assessment according to §35a Social Code Book V]
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Alemtuzumab, cladribine, dimethyl fumarate, fingolimod, natalizumab, ocrelizumab and teriflunomide for the treatment of adult patients with highly active relapsing remitting multiple sclerosis]
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Sacubitril/valsartan (heart failure, children and adolescents) – Benefit assessment according to §35a Social Code Book V]
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Secukinumab (hidradenitis suppurativa) – Benefit assessment according to §35a Social Code Book V]
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ravulizumab (neuromyelitis optica spectrum disorder [NMOSD]) – Benefit assessment according to §35a Social Code Book V]
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Lisocabtagene maraleucel (DLBCL, HGBCL, PMBCL and FL3B, each after one prior therapy) – Benefit assessment according to §35a Social Code Book V]
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Tremelimumab and durvalumab (hepatocellular carcinoma [HCC]) – Benefit assessment according to §35a Social Code Book V]
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Tremelimumab and durvalumab (hepatocellular carcinoma [HCC]) – Benefit assessment according to §35a Social Code Book V]
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Guideline synopsis for the update of the DMP “Coronary heart disease”]
2023	Agency for Healthcare Research and Quality (AHRQ)	Living systematic review on cannabis and other plant-based treatments for chronic pain
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Guideline synopsis for the update of the DMP “Depression”]
2023	Institut national d'excellence en sante et en services sociaux (INESSS)	[Guides and standards: wound care-assessment, management, and optimal treatment use]
2023	Institut national d'excellence en sante et en services sociaux (INESSS)	[State of knowledge: gene panel for the identification of myeloid mutations by NGS ‒ evaluation report on the repatriation of an analysis carried out outside of the province of Québec]
2023	Health Sciences Institute in Aragon (IACS)	[Incorporation of expanded genetic analysis to assist the assessment of venous thromboembolism risks and recurrent spontaneous miscarriages]
2023	Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)	[Computerized clinical decision support systems for decision support in patients with breast, lung, colorectal or prostate cancer]
2023	Health Technology Wales (HTW)	Renal denervation to treat people with resistant hypertension
2023	Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)	[Assessment of the volume-result relationship in specialized care of pediatric cancer]
2023	Scottish Health Technologies Group (SHTG)	Bacteriophage therapy for patients with difficult to treat bacterial infections
2023	Penn Medicine Center for Evidence-based Practice (CEP)	Update: Clinical risk prediction tools for venous thromboembolism in medical patients
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Tralokinumab (moderate-to-severe atopic dermatitis in adolescents) - Benefit assessment according to § 35a Social Code Book V]
2023	NIHR Health Technology Assessment programme	Mortality impact, risks, and benefits of general population screening for ovarian cancer: the UKCTOCS randomised controlled trial
2023	Agency for Healthcare Research and Quality (AHRQ)	Management of postpartum hypertensive disorders of pregnancy
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Daridorexant (chronic insomnia) - Benefit assessment according to § 35a SGB V]
2023	Institut national d'excellence en sante et en services sociaux (INESSS)	[Report: relevance of adding the HbS/E, HbE/E and HbE/β-thal variants to the primary targets of the neonatal screening test for hemoglobinopathies]
2023	NIHR Health Services and Delivery Research programme	Involving carer advisors in evidence synthesis to improve carers’ mental health during end-of-life home care: co-production during COVID-19 remote working